|Page (1) of 1 - 02/06/13||email article||print page|
(PRWEB) February 06, 2013
The growing body of published observational data showing significant and rapid improvement in physical motor impairments, spasticity, memory and cognitive function following perispinal Enbrel treatment warrants the commencement of rigorous clinical trials leading to the repurposing of Enbrel for the treatment of traumatic brain injury (TBI), stroke and Alzheimers disease. Physicians Augusto Ramirez, M.D.CEO of Neurological Wellness Center: http://www.neurological-recovery-guide.com/, Eugenia Siezar, M.D. and Meylin Acuna, M.D. petition the FDA to take immediate steps leading to the repurposing of Enbrel for the treatment of TBI, stroke and Alzheimers disease.
Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua, Nicaragua authorized this press release.
Today Neurological Wellness Center remains the only institution in the world providing individualized instructional courses teaching this perispinal Enbrel injection procedure. For more information about Neurological Wellness Centers perispinal Enbrel injection courses, visit: http://reversealzheimersnow.com/
In 2012 Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and e-book are now available online for $49. Visit: http://www.neurological-recovery-guide.com/
Perispinal Enbrel injections effectively treat conditions for which no other treatment is currently available. An observational study was published in December 2012 in the journal CNS Drugs and is available online, http://www.ncbi.nlm.nih.gov/pubmed/23100196
Systematically examined the clinical responses of 629 patients afflicted by stroke or traumatic brain injury following the perispinal administration of Enbrel (etanercept), the mean interval between stroke and perispinal Enbrel (PSE) treatment was 42 months. The mean interval between TBI and PSE treatment was 115 months. The fact that there is presently no FDA-approved treatment that can effectively ameliorate the impairments of stroke or TBI, 42 to 115 months after the event, makes it clear that PSE treatment satisfies the criteria qualifying for the FDAs fast track drug development program by demonstrating the potential to address unmet medical needs under section 506(a) of the Fast Track Drug Development Act. 4. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf. This is the only treatment of TBI that has the capacity to meaningfully restore function one year or longer after the brain injury.
The case for FDA fast tracking PSE for the treatment of Alzheimers disease is just as compelling. There have been more than a dozen published studies showing a significant and rapid cognitive improvement following PSE since Dr. Tobinicks ground-treaking pilot study published in the journal Medscape in 2006 and available online. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785182/. This is the only Alzheimer's disease treatment that enables the recovery of memory and cognitive function. Frequently this treatment of Alzheimer's disease results in noticeable improvements within minutes. One need only to engage in conversation or look into their eyes to notice a striking change.
Every day countless thousands of people in the U.S. and around the world must move to assisted living facilities because the drugs currently available are failing to halt the progression of this disease. We at Neurological Wellness Center lament that physicians from around the world must travel to Managua Nicaragua to receive this instruction. FDA approval of PSE as a treatment for TBI, stroke and Alzheimers disease would result in medical schools around the world incorporating perispinal Enbrel injection technique into the standard curriculum.
Enbrel has been approved for the treatment of rheumatoid arthritis and psoriasis since 1998. It is being aggressively marketed by Amgen/Pfizer earning them over $5 Billion annually. Over 400,000 Americans are currently taking Enbrel. A box of 25 mg vials typically retails for $1000. To purchase boxes of Enbrel for as low as $765/ box visit: http://www.genuine-enbrel-cheaper.com/. The safety parameters of Enbrel are well established. To access the 173 references in support of the assertions in this press release, click the file attachment at the right side of this page.
Neurological Wellness Center invites physicians and concerned lay persons to contact Amgen requesting the repurposing of Enbrel for the treatment of TBI, stroke and Alzheimer's disease, attention Huong Nguyen; medinfo(at)amgen(dot)com Tel: 805-447-1000 Fax: 805-447-1010.
Food and Drug Administration
Center for Drug Evaluation and Research
5600 Fishers Lane, Rockville, MD 20857
Read the full story at http://www.prweb.com/releases/2013/2/prweb10319406.htm.
Keywords:medical procedure/test,medical research,medical staff,medical specialisation,medical service,medical conditions
Related Sites: Digital Producer , Digital Producer , Hollywood Industry , Hollywood Industry , Digital Post Production , Digital Post Production , Film Imaging , Film Imaging , Oceania , Oceania , DMN Newswire , DMN Newswire , VideoBasedTutorials , VideoBasedTutorials , HTN - Health Technology Net , HTN - Health Technology Net
Related Newsletter: DMN Newsletter , DMN Newsletter , Digital Media Net , Digital Media Net , DMNForums , DMNForums , Tutorial Finder , Tutorial Finder , Review Seeker , Review Seeker